About Immorta Bio
Immorta Bio develops treatments for people with cancer, organ failure and age-related conditions. SenoMune helps the immune system identify and remove damaged cells that build up with age, known as senescent cells. StemCellRevivify uses young cells selected for specific organs to restore cell and tissue function. The combined approach targets both harmful cell accumulation and declining tissue repair.
Immorta Bio is based in Miami Beach. Boris Reznik is chairman and chief executive officer, and Thomas Ichim is president and chief scientific officer. Reznik has spent four decades building technology companies and directing programs that obtained drug and biologic approvals. Ichim has more than 20 years in biotechnology and has published over 130 peer-reviewed articles. The company works with researchers at four institutions, including the Buck Institute, Cedars-Sinai and the University of Miami.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2024 | Oct 16, 2026 | $612,503of $5.0M target | 6 | $102K | EquityRule 506(c) | Form D ↗ |
| Nov 9, 2023 | Jan 8, 2026 | $450,000of $500K target | 3 | $150K | EquityRule 506(c) | Form D ↗ |
| Total, two offerings | $1,062,503 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Immorta Bio
Immorta Bio is building immune and regenerative treatments for diseases tied to aging. Its case depends on distinct tools working together across several conditions. The programs were advancing from extensive preclinical work toward human clinical development.
The problem it targets
Immorta Bio argues that senescent cells are dysfunctional older cells that contribute to inflammation, organ failure and tumor growth. In its view, aging also reduces the number and strength of stem cells needed for repair. The company treats damaged-cell accumulation and lost regenerative capacity as linked problems. Its programs address those processes across cancer, organ failure and aging rather than use a separate biological approach for each condition.
What the product does
SenoMune is an immune treatment designed to help the body recognize and remove senescent cells. StemCellRevivify introduces young, organ-specific progenitor and mesenchymal stem cells to rebuild regenerative capacity. Earlier materials describe SenoVax as a senolytic immunotherapy tied to a vaccine patent application. Together, the programs aim to clear harmful cells while restoring cells needed to repair tissue.
Progress so far
On November 25, 2025, Immorta Bio announced publication of international patent application PCT/WO2025184665, titled “Senescence Vaccine.” It reported that SenoVax reduced tumors across five cancer types in animal models, including lung, breast and pancreatic cancers. The program was also the subject of FDA submission IND #30745 for advanced lung cancer. A combined treatment increased mean lifespan by more than 70% and median lifespan by more than 80% in aging models. NYU Stern selected Immorta Bio for its nine-month 2026–27 Endless Frontier Labs cohort.
How the market is moving
Boris Reznik sees biotechnology moving from artificial intelligence that improves existing processes toward AI embedded in therapeutic discovery, optimization and personalization. In his view, this shift matters especially in longevity and regenerative medicine, where treatments must reflect each person's biological profile. Immorta Bio presents AI as a tool for identifying targets, biomarkers and treatment strategies at scale.
We wrote this summary from public statements by Immorta Bio and its investors. It is not investment advice.
Immorta Bio in the News
Leadership Team
Executive officers and directors listed on Immorta Bio's Form D filed Oct 16, 2026.
